Roche (RHHBY) presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting.CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.However, shares of the company were down 6% on Sept. 11, post the presentation on concerns of side-effects from the investigational obesity drug.Year to date, Roche’s shares have gained 3.1% ...